María Araceli Caballero-Rabasco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María Araceli Caballero-Rabasco has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Laura Valdesoiro-Navarrete
Alergia y Neumología Pediátrica. Parc Taulí Hospital Universitari, I3PT-CERCA. Sabadell, Barcelona, Spain
5 shared publications - Alberto Bercedo-Sanz
Grupo de Vías Respiratorias de la Asociación Española de Pediatras de Atención Primaria (AEPAP), Madrid, Spain
3 shared publications - Catalina Lizano-Barrantes
Department of Pharmaceutical Care and Clinical Pharmacy, Faculty of Pharmacy, Universidad de Costa Rica, San José, Costa Rica
3 shared publications - Inés de Mir-Messa
Paediatric Pulmonology, Allergology and Cystic Fibrosis Unit, Hospital Universitario Materno Infantil Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
3 shared publications - Karina Mayoral
National Heart & Lung Institute Imperial College London London UK
3 shared publications - Manuel Praena-Crespo
Centro de Salud la Candelaria, Servicio Andaluz de Salud, Seville, Spain
3 shared publications
Latest Publications
- Open Access
- 12 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4188
Subcutaneous House Dust Mite Immunotherapy Effectiveness and Safety in a Paediatric Population: A Prospective Real-Life Study
Background/Objectives: Allergen immunotherapy is the sole therapeutic option capable of modifying the natural course of allergic rhinitis and preventing the development of asthma. Results from paediatric patients are scarce. To evaluate the effectiveness and safety of a glutaraldehyde-modified extract of mites (Beltavac®) administered for one year under clinical routine conditions in children between 3 and 11 years old. Methods: This was a multicentre, prospective, 13-month cohort study. Among 97 children diagnosed with immunoglobulin E-mediated house dust mite allergic rhinoconjunctivitis, 87 initiated the subcutaneous immunotherapy. The main outcomes included the Combined Symptoms and Medication Score (CSMS), assessed for 1 month at baseline and after 1, 6, and 12 months, and the number of adverse reactions according to the WAO adverse reaction grading system. The levels of serum-specific immunoglobulins were also assessed. Results: CSMS improved scores throughout therapy (adjusted mean change and 95% confidence interval: 0.55, 0.26–0.84 points; p < 0.001). Improvements occurred in both children with (n = 68) and without asthma (n = 19), as well as in children aged ≥6 years (n = 76) and <6 years (n = 11), although statistical significance was not reached in the smallest subgroups. Eight children (9.2%) developed a total of 15 adverse reactions. Most occurred after the initial dose (five out of eight children), and were local (six out of eight) and minor (five out of eight). Over 90% of patients completed the full regimen. Conclusions: This study supports the effectiveness and safety of allergen immunotherapy administered according to a rush schedule for one year for paediatric allergic rhinitis.
- 12 June 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (12) , 4188
Open AccessSubcutaneous House Dust Mite Immunotherapy Effectiveness and Safety in a Paediatric Population: A Prospective Real-Life Study
Background/Objectives: Allergen immunotherapy is the sole therapeutic option capable of modifying the natural course of allergic rhinitis and preventing the development of asthma. Results from paediatric patients are scarce. To evaluate the effectiveness and safety of a glutaraldehyde-modified extract of mites (Beltavac®) administered for one year under clinical routine conditions in children between 3 and 11 years old. Methods: This was a multicentre, prospective, 13-month cohort study. Among 97 children diagnosed with immunoglobulin E-mediated house dust mite allergic rhinoconjunctivitis, 87 initiated the subcutaneous immunotherapy. The main outcomes included the Combined Symptoms and Medication Score (CSMS), assessed for 1 month at baseline and after 1, 6, and 12 months, and the number of adverse reactions according to the WAO adverse reaction grading system. The levels of serum-specific immunoglobulins were also assessed. Results: CSMS improved scores throughout therapy (adjusted mean change and 95% confidence interval: 0.55, 0.26–0.84 points; p < 0.001). Improvements occurred in both children with (n = 68) and without asthma (n = 19), as well as in children aged ≥6 years (n = 76) and <6 years (n = 11), although statistical significance was not reached in the smallest subgroups. Eight children (9.2%) developed a total of 15 adverse reactions. Most occurred after the initial dose (five out of eight children), and were local (six out of eight) and minor (five out of eight). Over 90% of patients completed the full regimen. Conclusions: This study supports the effectiveness and safety of allergen immunotherapy administered according to a rush schedule for one year for paediatric allergic rhinitis.
- Open Access
- 18 October 2023
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 32 (170) , 230124
Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis
Background: We aim to assess the impact of montelukast on paediatric patients with asthma/allergic rhinitis, measured using patient-reported outcome measures, compared with other treatments or placebo.Methods: Protocol registration CRD42020216098 (www.crd.york.ac.uk/PROSPERO). MEDLINE and Embase databases were used to conduct the search. Two authors independently selected studies and extracted data, and a third reviewer resolved discrepancies. Meta-analyses were constructed to estimate the standardised mean difference (SMD) using a random-effects model.Results: Out of 3937 articles identified, 49 studies met the inclusion criteria, mostly randomised clinical trials (sample sizes: 21–689 patients). The SMD of change pooled estimators for the global, mental and physical domains of health-related quality of life were not statistically significant. For daytime and night-time symptoms scores, the SMD (95% CI) was in favour of inhaled corticosteroids (−0.12, −0.20– −0.05 and −0.23, −0.41– −0.06, respectively). The pooled estimator for global asthma symptoms was better for montelukast when compared with placebo (0.90, 0.44–1.36).Conclusions: The synthesis of the available evidence suggests that, in children and adolescents, montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms, especially at night-time. These findings of our systematic review concur with current guidelines for asthma treatment.
- 18 October 2023
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 32 (170) , 230124
Open AccessMontelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis
Background: We aim to assess the impact of montelukast on paediatric patients with asthma/allergic rhinitis, measured using patient-reported outcome measures, compared with other treatments or placebo.Methods: Protocol registration CRD42020216098 (www.crd.york.ac.uk/PROSPERO). MEDLINE and Embase databases were used to conduct the search. Two authors independently selected studies and extracted data, and a third reviewer resolved discrepancies. Meta-analyses were constructed to estimate the standardised mean difference (SMD) using a random-effects model.Results: Out of 3937 articles identified, 49 studies met the inclusion criteria, mostly randomised clinical trials (sample sizes: 21–689 patients). The SMD of change pooled estimators for the global, mental and physical domains of health-related quality of life were not statistically significant. For daytime and night-time symptoms scores, the SMD (95% CI) was in favour of inhaled corticosteroids (−0.12, −0.20– −0.05 and −0.23, −0.41– −0.06, respectively). The pooled estimator for global asthma symptoms was better for montelukast when compared with placebo (0.90, 0.44–1.36).Conclusions: The synthesis of the available evidence suggests that, in children and adolescents, montelukast was effective in controlling asthma symptoms when compared with placebo, but inhaled corticosteroids were superior in controlling symptoms, especially at night-time. These findings of our systematic review concur with current guidelines for asthma treatment.
- 8 April 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (4) , e13942
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
- 8 April 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (4) , e13942
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
- Open Access
- 6 March 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 19 (8) , 798-804
Inhaler Technique Questionnaire (InTeQ) in pediatric patients with asthma
- 6 March 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 19 (8) , 798-804
Open AccessInhaler Technique Questionnaire (InTeQ) in pediatric patients with asthma
- 1 March 2021
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 57 (3) , 186-194
Implementación de un panel de genes para el diagnóstico genético de la discinesia ciliar primaria
- 1 March 2021
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 57 (3) , 186-194
Implementación de un panel de genes para el diagnóstico genético de la discinesia ciliar primaria
- 22 February 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5) , 980-991
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date.Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow‐up. The primary outcome was the evolution of the annual number of moderate‐to‐severe exacerbations compared with the baseline period.Results: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution.Conclusion: In this large, long‐term, observational study, moderate‐to‐severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long‐term treatment in pediatric patients with severe persistent allergic asthma.
- 22 February 2021
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 32 (5) , 980-991
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma
Background: Various studies have assessed omalizumab outcomes in the clinical practice setting but follow‐up and/or number of patients included were limited. We aim to describe the long‐term outcomes of pediatric patients with severe persistent allergic asthma receiving omalizumab in the largest real‐life cohort reported to date.Methods: ANCHORS was a multicenter, observational, retrospective cohort study conducted in 25 Pediatric Allergy and Pulmonology units in Spain. We collected data of patients < 18 years and initiating omalizumab between 2006 and 2018, from the year prior to omalizumab initiation to discontinuation or last available follow‐up. The primary outcome was the evolution of the annual number of moderate‐to‐severe exacerbations compared with the baseline period.Results: Of the 484 patients included, 101 (20.9%) reached 6 years of treatment. The mean ± standard deviation number of exacerbations decreased during the first year of treatment (7.9 ± 6.6 to 1.1 ± 2.0, P < .001) and remained likewise for up to 6 years. The other clinical parameters assessed also improved significantly during the first year and stabilized or continued to improve thereafter. The percentage of patients experiencing adverse events was consistently low, and the main reason for discontinuation was good disease evolution.Conclusion: In this large, long‐term, observational study, moderate‐to‐severe exacerbations decreased significantly from the first year of treatment with omalizumab. The beneficial effect was maintained in the long term, along with a good safety profile. Our results position omalizumab as an effective long‐term treatment in pediatric patients with severe persistent allergic asthma.
- 2 January 2021
- Published by Springer Nature in Quality of Life Research
- Vol. 30 (11) , 3127-3144
Smartphone App for monitoring Asthma in children and adolescents
Purpose The asthma stepwise treatment approach recommended is based on monitoring patients’ symptoms. The Asthma Research in Children and Adolescents (ARCA) cohort was created to provide evidence about the evolution of persistent asthma. This manuscript describes the development of an electronic health tool, comprising a mobile health application for patients with asthma and its associated online platform for pediatricians to monitor them. Methods The development process followed 7 phases: the first 5 (Conceptualization, Preparation, Assessment scheduling, Image and user interface, and Technical development) defined and designed the tool, followed by a testing phase (functionality assessment and pilot test with ARCA patients), and a last phase which evaluated usability. Since the target population was aged 6–16 years, three versions were designed within the same smartphone application: parents/proxy, children, and adolescents. The online platform for pediatricians provides real-time information from the application: patients’ responses over time with color-coded charts (red/amber/green, as in traffic lights). Results The pilot test through semi-structured phone interviews of the first 50 participants included in the ARCA study (n = 53) detected their misunderstandings. Pediatricians were trained to emphasize that the application is free of charge and requires monthly answers. Median of the System Usability Scale scores (n = 85), ranging 0 (negative)–100 (positive), was > 93 in the three age versions of the application. Conclusions Technology has the capability of transforming the use of patient-reported outcomes. Describing all the development phases of a mobile health application for monitoring children and adolescents with asthma may increase the knowledge on how to design applications for young patients.
- 2 January 2021
- Published by Springer Nature in Quality of Life Research
- Vol. 30 (11) , 3127-3144
Smartphone App for monitoring Asthma in children and adolescents
Purpose The asthma stepwise treatment approach recommended is based on monitoring patients’ symptoms. The Asthma Research in Children and Adolescents (ARCA) cohort was created to provide evidence about the evolution of persistent asthma. This manuscript describes the development of an electronic health tool, comprising a mobile health application for patients with asthma and its associated online platform for pediatricians to monitor them. Methods The development process followed 7 phases: the first 5 (Conceptualization, Preparation, Assessment scheduling, Image and user interface, and Technical development) defined and designed the tool, followed by a testing phase (functionality assessment and pilot test with ARCA patients), and a last phase which evaluated usability. Since the target population was aged 6–16 years, three versions were designed within the same smartphone application: parents/proxy, children, and adolescents. The online platform for pediatricians provides real-time information from the application: patients’ responses over time with color-coded charts (red/amber/green, as in traffic lights). Results The pilot test through semi-structured phone interviews of the first 50 participants included in the ARCA study (n = 53) detected their misunderstandings. Pediatricians were trained to emphasize that the application is free of charge and requires monthly answers. Median of the System Usability Scale scores (n = 85), ranging 0 (negative)–100 (positive), was > 93 in the three age versions of the application. Conclusions Technology has the capability of transforming the use of patient-reported outcomes. Describing all the development phases of a mobile health application for monitoring children and adolescents with asthma may increase the knowledge on how to design applications for young patients.
- Open Access
- 9 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3603
Immunofluorescence Analysis as a Diagnostic Tool in a Spanish Cohort of Patients with Suspected Primary Ciliary Dyskinesia
Primary ciliary dyskinesia (PCD) is an autosomal recessive rare disease caused by an alteration of ciliary structure. Immunofluorescence, consisting in the detection of the presence and distribution of cilia proteins in human respiratory cells by fluorescence, has been recently proposed as a technique to improve understanding of disease-causing genes and diagnosis rate in PCD. The objective of this study is to determine the accuracy of a panel of four fluorescently labeled antibodies (DNAH5, DNALI1, GAS8 and RSPH4A or RSPH9) as a PCD diagnostic tool in the absence of transmission electron microscopy analysis. The panel was tested in nasal brushing samples of 74 patients with clinical suspicion of PCD. Sixty-eight (91.9%) patients were evaluable for all tested antibodies. Thirty-three cases (44.6%) presented an absence or mislocation of protein in the ciliary axoneme (15 absent and 3 proximal distribution of DNAH5 in the ciliary axoneme, 3 absent DNAH5 and DNALI1, 7 absent DNALI1 and cytoplasmatic localization of GAS8, 1 absent GAS8, 3 absent RSPH9 and 1 absent RSPH4A). Fifteen patients had confirmed or highly likely PCD but normal immunofluorescence results (68.8% sensitivity and 100% specificity). In conclusion, immunofluorescence analysis is a quick, available, low-cost and reliable diagnostic test for PCD, although it cannot be used as a standalone test.
- 9 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3603
Open AccessImmunofluorescence Analysis as a Diagnostic Tool in a Spanish Cohort of Patients with Suspected Primary Ciliary Dyskinesia
Primary ciliary dyskinesia (PCD) is an autosomal recessive rare disease caused by an alteration of ciliary structure. Immunofluorescence, consisting in the detection of the presence and distribution of cilia proteins in human respiratory cells by fluorescence, has been recently proposed as a technique to improve understanding of disease-causing genes and diagnosis rate in PCD. The objective of this study is to determine the accuracy of a panel of four fluorescently labeled antibodies (DNAH5, DNALI1, GAS8 and RSPH4A or RSPH9) as a PCD diagnostic tool in the absence of transmission electron microscopy analysis. The panel was tested in nasal brushing samples of 74 patients with clinical suspicion of PCD. Sixty-eight (91.9%) patients were evaluable for all tested antibodies. Thirty-three cases (44.6%) presented an absence or mislocation of protein in the ciliary axoneme (15 absent and 3 proximal distribution of DNAH5 in the ciliary axoneme, 3 absent DNAH5 and DNALI1, 7 absent DNALI1 and cytoplasmatic localization of GAS8, 1 absent GAS8, 3 absent RSPH9 and 1 absent RSPH4A). Fifteen patients had confirmed or highly likely PCD but normal immunofluorescence results (68.8% sensitivity and 100% specificity). In conclusion, immunofluorescence analysis is a quick, available, low-cost and reliable diagnostic test for PCD, although it cannot be used as a standalone test.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA385
Preliminary results of high-speed video-microscopy and immunofluorescence analysis in a Spanish cohort of patients with primary ciliary dyskinesia
Background: Primary ciliary dyskinesia (PCD) diagnosis is based on studying ciliary function by high-speed video-microscopy (HSVM) and ciliary ultrastructure by transmission electron microscopy (TEM). Immunofluorescence (IF) analysis has been proposed as a routine test to improve PCD diagnosis rate. We show a preliminary HSVM and IF results of PCD candidate patients Methods: A cohort of patients was studied because of high clinical suspicion of PCD. Samples of ciliated nasal epithelium were obtained by brushing. HSVM for analysing ciliary beat frequency (CBF, normal ≥9Hz) and pattern (CBP, normal ≤20% dyskinetic ciliated cells) was performed using a high-speed camera and optical microscope. Samples from 30 patients were prepared for IF analysis and labelled with a panel of 4 ciliary-ultrastructure antibodies: DNAH5, DNALI1, GAS8, RSPH4A Results: We present HSVM and IF results of 30 patients. HSVM analyses showed 22 (73%) patients presented a reduced CBF and 28 (93%) an altered CBP (12 had disorganised ciliary beat, 10 immotile cilia and 6 stiff cilia). Regarding IF analysis, 23 (77%) were evaluable for all antibodies: 14 were normal and 9 had one or moreabsent proteins (6 DNAH5, 1 DNALI1, 1 DNAH5 and DNALI1 and 1 DNAH5, DNALI1 and GAS8). All cases with a defect in IF presented a concordant CBP. Only one case with a normal IF had also a normal HSVM. The other 13 cases had a normal IF but an altered CBP, for which further studies are being performed Conclusion: The combination of HSVM and IF could explain an important number of cases, although other analyses will be necessary to increase the accuracy and diagnosis rate of PCD
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA385
Preliminary results of high-speed video-microscopy and immunofluorescence analysis in a Spanish cohort of patients with primary ciliary dyskinesia
Background: Primary ciliary dyskinesia (PCD) diagnosis is based on studying ciliary function by high-speed video-microscopy (HSVM) and ciliary ultrastructure by transmission electron microscopy (TEM). Immunofluorescence (IF) analysis has been proposed as a routine test to improve PCD diagnosis rate. We show a preliminary HSVM and IF results of PCD candidate patients Methods: A cohort of patients was studied because of high clinical suspicion of PCD. Samples of ciliated nasal epithelium were obtained by brushing. HSVM for analysing ciliary beat frequency (CBF, normal ≥9Hz) and pattern (CBP, normal ≤20% dyskinetic ciliated cells) was performed using a high-speed camera and optical microscope. Samples from 30 patients were prepared for IF analysis and labelled with a panel of 4 ciliary-ultrastructure antibodies: DNAH5, DNALI1, GAS8, RSPH4A Results: We present HSVM and IF results of 30 patients. HSVM analyses showed 22 (73%) patients presented a reduced CBF and 28 (93%) an altered CBP (12 had disorganised ciliary beat, 10 immotile cilia and 6 stiff cilia). Regarding IF analysis, 23 (77%) were evaluable for all antibodies: 14 were normal and 9 had one or moreabsent proteins (6 DNAH5, 1 DNALI1, 1 DNAH5 and DNALI1 and 1 DNAH5, DNALI1 and GAS8). All cases with a defect in IF presented a concordant CBP. Only one case with a normal IF had also a normal HSVM. The other 13 cases had a normal IF but an altered CBP, for which further studies are being performed Conclusion: The combination of HSVM and IF could explain an important number of cases, although other analyses will be necessary to increase the accuracy and diagnosis rate of PCD
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , PA4154
Development of lung function in infancy in 'healthy' preterm infants
Even in the absence of overt respiratory disease during the neonatal period, reduced lung function (LF) has been reported in preterm infants. We have previously found significantly lower Crs, V'maxFRC, FEV0.5 and FEF25-75 in “healthy” preterm infants when compared to term controls (ERS de Mir, 2014) Objectives: To assess LF at 6 and 18 months of age in preterm infants without neonatal respiratory disease, and compare the measurements to those obtained in healthy fullterm infants. Methods: LF was measured under chloral sedation in 'healthy' preterm (30-35.8 w) and fullterm Spanish White babies, using the CareFusionTM Masterscreen BabyBody equipment. Results were expressed as z scores to adjust for sex, age and body size (Lum, Ped Pulm 2010; Nguyen, Ped Pulm 2013). Results: 156 infants were initially studied at mean (SD) corrected postnatal age (cPNA) of 5.9 (1.0) months. 112 (57 term and 55 preterm) were followed up at 18.3 and 18.2 months respectively. At 18 months cPNA, results were similar between the groups LFT follow up at 18 m cPNA Conclusions: The differences observed in our cohort between term controls and 'healthy' preterm infants at 6 months cPNA in Crs, V'maxFRC, FEV 0,5 and FEF 25-75% was no longer evident at 18 months corrected age, suggesting a catch-up of lung function in this group of preterm infants.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , PA4154
Development of lung function in infancy in 'healthy' preterm infants
Even in the absence of overt respiratory disease during the neonatal period, reduced lung function (LF) has been reported in preterm infants. We have previously found significantly lower Crs, V'maxFRC, FEV0.5 and FEF25-75 in “healthy” preterm infants when compared to term controls (ERS de Mir, 2014) Objectives: To assess LF at 6 and 18 months of age in preterm infants without neonatal respiratory disease, and compare the measurements to those obtained in healthy fullterm infants. Methods: LF was measured under chloral sedation in 'healthy' preterm (30-35.8 w) and fullterm Spanish White babies, using the CareFusionTM Masterscreen BabyBody equipment. Results were expressed as z scores to adjust for sex, age and body size (Lum, Ped Pulm 2010; Nguyen, Ped Pulm 2013). Results: 156 infants were initially studied at mean (SD) corrected postnatal age (cPNA) of 5.9 (1.0) months. 112 (57 term and 55 preterm) were followed up at 18.3 and 18.2 months respectively. At 18 months cPNA, results were similar between the groups LFT follow up at 18 m cPNA Conclusions: The differences observed in our cohort between term controls and 'healthy' preterm infants at 6 months cPNA in Crs, V'maxFRC, FEV 0,5 and FEF 25-75% was no longer evident at 18 months corrected age, suggesting a catch-up of lung function in this group of preterm infants.